April 11, 2014
Global Epinephrine Auto-Injector Market Report
DUBLIN, Ireland, April 11, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/53hl65/global)
has announced the addition of the "Global Epinephrine Auto-Injector Market Report"
[http://www.researchandmarkets.com/research/53hl65/global ] report to their offering.
The analysts forecast the Global Epinephrine Auto-injector market to grow at a CAGR of
13.34 percent over the period 2012-2016. One of the key factors contributing to this
market growth is the increasing prevalence of allergies. The Global Epinephrine
Auto-injector market has also been witnessing the development of chlorofluorocarbon-free
epinephrine auto-injector inhalers. However, the adverse side-effects of epinephrine drugs
could pose a challenge to the growth of this market.
The report, the Global Epinephrine Auto-injector Market Report, has been prepared
based on an in-depth market analysis with inputs from industry experts. The report covers
the market in the Americas and the EMEA and APAC regions; it also covers the Global
Epinephrine Auto-injector market landscape and its growth prospects in the coming years.
The report also includes a discussion of the key vendors operating in this market.
The inhalers used for the treatment of asthma patients in the past combined a mixture
of epinephrine powder [http://www.researchandmarkets.com/research/53hl65/global ] and CFC
as an aerosol. However, the government in the US imposed a ban on the use of CFC as a
propellant in inhalers. Primatene Mist, the only FDA-approved over-the-counter epinephrine
inhaler containing CFC, was pulled by the FDA on December 31, 2011. Primatene Mist was the
only FDA-approved epinephrine inhaler available in the market for the temporary relief of
occasional symptoms of mild asthma. Hence, vendors are increasing their investment in R&D
to develop a CFC-free epinephrine inhaler using hydrofluoroalkane as a propellant.
According to the report, though epinephrine is produced in the body, chemically
synthesized epinephrine drugs are used in the treatment of anaphylactic shock that occurs
in people who are suffering from allergy, cardiac arrest, and asthma. The increase in the
number of people who are allergic to food, food additives, dust, and insect venom has led
to an increase in the use of epinephrine drugs. This is one of the major factors that
drive the growth of the Global Epinephrine Auto-injector market.
Further, the report states that one of the main challenges in the market is that
epinephrine drugs [http://www.researchandmarkets.com/research/53hl65/global ] can cause
adverse side effects such as vomiting, cardiac arrhythmia, hyperuricemia, lactic acidosis,
pulmonary edema, and cerebral hemorrhage. Hence, physicians prefer to prescribe
immunotherapy and other alternative pharmacotherapy drugs for the treatment of allergies.
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Key Leading Countries
9. Rate of Incidence and Prevalence
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
- Adamis Pharmaceuticals Corp. - ALK Abello - Amedra Pharmaceuticals - Antares Pharma - Hospira - Intelliject - Lincoln Medical - Mylan - Sanofi - Teva Pharmaceuticals Industries
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets